Do higher drug costs lead to better health?

Canadian Journal of Clinical Pharmacology

Volumn 12, Issue 1, 2005, Pages

  Mintzes, Barbara ^a   Lexchin, Joel ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

Burden of illness; Cost effectiveness; Drugs; Health care costs; Pharmaceuticals

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DONEPEZIL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART DISEASE; HIP FRACTURE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PRESCRIPTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 30744432118     PISSN: 1198581X     EISSN: 17106222     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Han D, Wang E. The value of medicines in Canada. Can J Clin Pharmacol Vol 12(1) Winter 2005:e10-e21; Jan. 7, 2005.
2. Canadian Institute for Health Information. Drug Expenditure in Canada 1985-2003. Ottawa: 2004. Available at: www.cihi.ca. Accessed September 2004.
3. Pierson, R. Merck pulls arthritis drug from market. Reuters: New York. Thursday September 30. Available at: http://www.reuters.co.uk/newsArticle.jhtml? type= healthNews&storyID=6382332§ion=news. Accessed: October, 2004.
4. Bombardier C, Laine L, Reicia A et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
5. Therapeutics Initiative. Cox-2 inhibitors: are they safer NSAIDs? Therapeutics Letter 39: January-February 2001. Available at: http://www.ti.ubc.ca/PDF/39.PDF. Accessed: October 2004.
6. Prescrire International. A Look Back at 2000: Overabundance and Deregulation. 2001; 10 (February): 52-54.
7. Patented Medicines Pricing Review Board. Annual Report 2000. Available at: http://www.pmprb-cepmb.gc.ca/CMFiles/ar00e812NPN-482003-6735.pdf. Accessed September 2004.
8. Patented Medicines Pricing Review Board. Annual Report 2002; Available at: http://www.pmprb-cepmb.gc.ca/CMFiles/pmprb2002ar30HCJ-9132004-7433.pdf. Accessed September 2004.
9. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood) 2001; 20(5): 241-51.
10. Lanctot KL, Hermann N, Yau KK, Khan LR, Liu BA, Loulou MM, Einarson TR. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-564.
11. AD2000 Collaborative Group. Longterm donepezil treatment in 565 patients with Alzheimer's Disease: randomised double-blind trial. Lancet 2004; 363: 2105-2115.
12. Saver BG, Woods NF, Taylor TR, Stevens NG. Physician policies on the use of preventative hormone therapy. American Journal of Preventive Medicine 1997; 13(5): 358-365.
13. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998; 5: 226-9.
14. Hulley, Stephen, Grady, Deborah, Bush, Trudy, Furberg, Curt, Herrington, David, Riggs, Betty, Vittinghoff, Eric, for the Heart and Estrogen/progestin Replacement Study Research Group. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 1998; 280: 605-613.
15. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
16. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB. Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial. JAMA 2003; 290(13): 1729-1738.
17. Therapeutics Initiative. Do Statins have a role in primary prevention? Therapeutics Letter 48; April-June 2003. Available at: http://www.ti.ubc.ca/PDF/ 48.pdf. Accessed September 2004.
18. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Archives of General Psychiatry 2000; 57, 311-317.
19. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The Emperor's New Drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 2002; 5: Article 23. Available at: http://www.journals.apa.Org/prevention/volume5/p re0050023a.html. Accessed September 2004.
20. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617.
21. Morgan S, Bassett, K, Mintzes B. Outcomes-based drug coverage in British Columbia. Health Affairs 2004; 23(3): 269-276.
22. Wazana A. Physicians and the Pharmaceutical Industry. Is a Gift Ever Just a Gift? JAMA 2000; 283:3:373-380.
23. Lexchin J. Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? CMAJ 1997; 156(3): 351-356.
24. CCOHTA. Canadian Expert Drug Evaluation Committee. Reason for Recommendation on Reconsideration and Reasons for Recommendation. Norelgestromin/Ethinyl Estradiol Transdermal Patch. Available at: http://www.ccohta.ca/CDR/cdrjdf/cdr_submissio ns/Complete/cdr_complete_Evra_06- 23-04.pdf. Accessed September 2004.
25. Rowsell LB. Advertising campaigns of branded and unbranded messages [policy statement]. Ottawa: Health Canada, Therapeutic Products Directorate; 2000. Available at: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adv_campaign_e. html (updated 2003 Jan 30); Accessed June 2003.
26. Jøldal B. Regulation for need-the Norwegian experience, J Soc Admin Pharm 1984; 2: 81-84.